Immorta Bio to Unveil SenoVax™ Cancer Therapy Findings at AAI Annual Meeting

Immorta Bio to Present at AAI 2025

Immorta Bio Inc, an innovative company dedicated to extending healthy longevity through advanced medical technologies, is gearing up to present its significant findings on SenoVax™, a pioneering senolytic immunotherapy targeting cancer, at the upcoming American Association of Immunologists (AAI) Annual Meeting. This esteemed event will provide a platform for Immorta Bio to showcase its cutting-edge approach to treating aging and age-related diseases, alongside prominent organizations like Pfizer and the University of Pittsburgh.

This year's Clinical Immunology Symposium, scheduled for May 5, 2025, will be held at the Hawaii Convention Center. Immorta Bio's session, titled "Immunologically Mediated Senolysis," is set for 8:15 AM to 10:15 AM in Room 316C. The company is excited to share its groundbreaking data and insights that position senolytic therapies as a vital component in fighting cancers while also addressing the aging process directly.

Understanding Senolytic Immunotherapy

Unlike traditional cancer treatments that typically target tumors indiscriminately, SenoVax™ is designed to train patients' immune systems to selectively recognize and destroy senescent cells. These cells accumulate in the body as we age, contributing to various health issues and acting as a barrier to immune responses against cancer. Immorta Bio’s innovative therapy aims to reduce this barrier, enhancing the immune system’s ability to combat malignancies effectively.

Preclinical studies show that SenoVax™ can effectively eliminate various cancer types, including lung, breast, pancreatic, and brain cancers, as well as melanoma. The results from animal models are promising, indicating that this novel approach could significantly improve outcomes for cancer patients by revitalizing their immune response.

Dr. Thomas Ichim, Immorta Bio's President and Chief Scientific Officer, expressed his enthusiasm about the opportunity to present at such a prestigious forum. He stated, "The chance to share our research on leveraging the immune system in the fight against cancer and aging is truly an exciting moment for our team."

Additionally, the company has collaborated with institutions such as the University of California San Diego and Georgetown University to delve deeper into the T cell-mediated mechanisms that underpin the anticancer effects of SenoVax™. There is also emerging evidence that natural killer cell activation plays a significant role in inducing tumor destruction as a consequence of this therapy.

Strategic Vision and Future Directions

Dr. Boris Reznik, the President and CEO of Immorta Bio, emphasizes that the company's foundation rests on 'Scientific Longevity.' He remarked, "Our selection to present at AAI 2025 not only validates our research but also highlights the importance of targeting the root causes of aging and cancer as intertwined processes."

With a commitment to tackling diseases of aging alongside traditional cancer therapies, Immorta Bio Inc. is poised to contribute significantly to the fields of gerontology and oncology. By harnessing the potential of scientific advancements, the company aims to redefine treatments for age-related ailments, fostering healthier lives and extending longevity.

As the medical community continues to explore the intricacies of the immune system's role in cancer, Immorta Bio’s illuminating presentations at the AAI Annual Meeting could pave the way for innovative strategies in treating both aging and cancer, further positioning the company at the forefront of longevity science.

For more information about Immorta Bio and its ongoing research initiatives, please check their official website at immortabio.com. Follow their journey on LinkedIn and X to stay updated on the latest breakthroughs in senolytic immunotherapy and aging-related health advancements.